H.C. Wainwright analyst Robert Burns assumed coverage of Karyopharm (KPTI) with a Buy rating and $27 price target The firm believes the company’s investigation into maintenance therapy for the solid tumor indication is “risk-mitigated.” Karyopharmhas “several significant data catalysts” that could drive investor interest, the analyst tells investors in a research note.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KPTI:
- Karyopharm Therapeutics Stockholders Approve Equity Plan Amendment
- Karyopharm’s Earnings Call: Clinical Gains Amid Financial Strains
- Karyopharm abstract selected for presentation at 2025 EHA meeting
- Karyopharm price target lowered to $33 from $43 at RBC Capital
- Karyopharm price target lowered to $42 from $54 at Baird